{"id":"W4379281665","doi":"10.1200/jco.2023.41.16_suppl.tps5623","title":"Exactis-03: A phase I trial of the combination of olaparib and navitoclax in women with high grade serous ovarian cancer and triple negative breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Université de Montréal; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Olaparib; Triple-negative breast cancer; Medicine; Ovarian cancer; PARP inhibitor; PALB2; Cancer research; Cancer; BRCA mutation; Oncology; Breast cancer; Internal medicine; Germline mutation; Biology; Mutation; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009783542,0.001116219,0.001283543,0.000425641,0.0002702013,0.0009255374,0.001069931,0.001380637,0.005814081],"category_scores_gemma":[0.000669502,0.0004857067,0.001059927,0.0005493569,0.0008869058,0.0007166092,0.0004869201,0.002018026,0.000919498],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009641029,"about_ca_system_score_gemma":0.001908736,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001312728,"about_ca_topic_score_gemma":0.004019684,"domain_scores_codex":[0.9997869,0.00008642206,0.00001448296,0.00003549299,0.00002511402,0.00005150767],"domain_scores_gemma":[0.9995936,0.00004874334,0.00008453234,0.00002798947,0.0000213781,0.0002238845],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.750043,0.03435475,0.007534982,0.002174078,0.00143215,0.000576569,0.0003379054,0.003642602,0.02700673,0.0008776448,0.006342311,0.1656774],"study_design_scores_gemma":[0.6589457,0.3221074,0.009931129,0.0001003061,0.0004015648,0.0006162751,0.0001086051,0.001246315,0.001989234,0.0004785492,0.004041267,0.00003359917],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9794471,0.005654175,0.0005299877,0.001118815,0.0002203205,0.004545897,0.00245112,0.0002566578,0.005776002],"genre_scores_gemma":[0.9777756,0.004242951,0.001799115,0.001777961,0.000182629,0.003601467,0.003949534,0.00003427107,0.006636403],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005814081,"threshold_uncertainty_score":0.01945001,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09415033928534335,"score_gpt":0.4692976871396335,"score_spread":0.3751473478542902,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}